WHO ICTRP trial

Evaluation of the Radioprotective Effect of Famotidine Against Radiotherapy…

ACTRN12612000101886 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting

Key facts

Trial ID ACTRN12612000101886
Public title Evaluation of the Radioprotective Effect of Famotidine Against Radiotherapy- induced Acute Toxicity in Patients with Prostate Cancer
Scientific title A Randomized controled trial of Famotidine as a Radioprotector agent versus Placebo before External Beam Radiotherapy in Patients with Prostate Cancer to Reduce Radiation- induced Acute Bowel & Urinary Toxicity using RTOG Criteria
Primary sponsor School of Paramedical Sciences, Shahid Beheshti Medical University,
Secondary sponsors Abolfazl Razzaghdoust
Registry Australian New Zealand Clinical Trials Registry (ANZCTR)
Recruitment status Not Recruiting
Study type Interventional
Phase Phase 1 / Phase 2
Countries Iran, Islamic Republic Of
Conditions Prostate Cancer;Bowel toxicity;Urinary toxicity; Prostate Cancer Bowel toxicity Urinary toxicity;Cancer - Prostate;Oral and Gastrointestinal - Normal oral and gastrointestinal development and function;Renal and Urogenital - Normal…
Interventions Oral Famotidine 40mg is administrated daily for 2 months twice per day before 2 months Radiotherapy: Once 4 hours before and the other 3 hours before daily Radiotherapy. A Physician determines Bowel & Urinary Toxicities Grade for the…
Registration date Jan 20, 2012
Target size 36
Secondary IDs Nil
Registry page anzctr.org.au

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations